Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-α

Journal of Pharmaceutical Sciences

Volumn 90, Issue 2, 2001, Pages 124-133

  Hartsel, Scott C ^a,b   Baas, Bradley ^a   Bauer, Emily ^a   Foree Jr , L Tuck ^a   Kindt, Katie ^a   Preis, Hilary ^a   Scott, Angela ^a   Kwong, Evan H ^b   Ramaswamy, Manisha ^b   Wasan, Kishor M ^b  

^a UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antifungal; Drug delivery; Liposome; Polyene

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SERUM ALBUMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABSORPTION SPECTROSCOPY; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG STABILITY; HEATING; HUMAN; HUMAN TISSUE; MONOCYTE;

EID: 0035136092     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200102)90:2<124::AID-JPS3>3.0.CO;2-X     Document Type: Article

References (39)

1. Amphotericin B: New life for an old drug
2. How do the polyene macrolide antibiotics affect the cellular membrane properties?
3. A comparative review of conventional and lipid formulations of amphotericin B
4. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: A new way to improve its therapeutic index
5. Physico-chemical properties of the heat-induced "superaggregates" of amphotericin B
6. Mild heating of amphotericin B-desoxycholate: Effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice
7. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating
8. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani
9. Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form
10. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins
11. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein
12. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs
13. Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin
14. Diversity of lipid-based polyene formulations and their behavior in biological systems
15. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: Single-dose studies
16. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins
17. Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity
18. Preferential distribution of amphotericin B lipid complex into human HDL(3) is a consequence of high density lipoprotein coat lipid content
19. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers
20. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: Lipid state and cholesterol content dependence
21. Association of the polyene antibiotic amphotericin B with phospholipid vesicles: Perturbation by temperature changes
22. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium
23. Circular dichroism for the determination of amphotericin B binding to liposomes
24. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells
25. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems
26. Comparative binding of bile acids to serum lipoproteins and albumin
27. The effect of serum albumin on the aggregation state and toxicty of nystatin
28. The formation of amphotericin B ion channels in lipid bilayers
29. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
30. Carrier effects on biological activity of amphotericin B
31. Amphotericin B activation of human genes encoding for cytokines
32. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: An effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone
33. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells
34. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B
35. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
36. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B
37. Amphotericin B-induced interleukin-1β expression in human monocytic cells is calcium and calmodulin dependent
38. Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages